InvestWiser

S2Medical AB

S2MNasdaq StockholmHealthcareMarket value 4 m SEK
0.00SEK 0.0%
last day · Price as of 19 November 2026

The answer first

Does S2Medical beat the market?

No, S2Medical has not beaten the market over the last year.

S2Medical−59.0%Stockholm (OMXSGI)+17.7%

Max for seven days

Follow S2Medical with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on S2Medical

From today, at a price of 0.00 SEK. Write why you follow S2Medical, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about S2Medical

Your first answer is free, no account needed.

Do you own S2Medical, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with S2Medical and a few more. Free, no card.

Past year against the exchange and Super Stock
S2Medical−59.0%Stockholm (OMXSGI)+17.7%Super Stock+46.3%
18 November 202519 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • S2Medical has fallen 59.0% over the past year, including dividends.
  • The largest fall over the past three years was 99.3%. The price is 100.0% below its peak now.

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

Quality34
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 153 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.00
  • Asset turnoverSales divided by everything the company owns0.96
  • Return on equityProfit divided by equity−100.1%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value–
The price · Valuation: the multiples
  • P/BPrice divided by equity0.3
  • P/SPrice divided by sales0.2
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend7
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 166 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−50.0%
  • 6 months−28.9%
  • 9 months−64.0%
  • 12 months−59.0%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−11.1%
3 years, per year
−37.5%
5 years, per year
−66.3%
Year to date
−59.5%
Largest fall, 3 years
−99.3%
From a peak to the bottom
From the peak now
−100.0%
How far the price is from the peak
Volatility, 1 year
165.7%
How much the price swings over a year
Beta, 1 year
−0.35
How much the price moves when the market moves

Return with dividends reinvested.

About S2Medical

S2Medical AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 10 employees.

S2Medical AB (publ) develops products for wound healing, infection control, and cosmeceuticals spectrum in Sweden. The company offers odor eliminator under the YNOLENS brand; IvaQ, a negative pressure wound therapy (NPWT) system; Instagraft, a technology designed to make skin transplantation even in non-specialist healthcare setting; ADMERCIN, a solution against antibiotic-resistant bacteria; and Epiprotect, a technology designed to protect and support wound healing by creating an environment for tissue recovery.

See the full analysis of S2Medical.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market